oup entities and are 
valued at acquisition cost. Most of these shares 
are held by the Group to cover the Stock Option 
Plans and have been acquired in the previous 
years with the aim of hedging against share price 
fluctuations. In 2023, the changes of Revaluation reserves - 
Equity instruments at fair value through Profit or 
Loss is related to the reevaluation at fair value 
of the other investment in ScandiDos A.B (EUR 
-0.2 million) and HIL applied Medical Ltd (EUR -
2.8 million), see Note 5.5.